Neuren Pharmaceuticals Ltd
ASX:NEU
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
12.25
25.11
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one NEU stock under the Base Case scenario is 8.13 AUD. Compared to the current market price of 12.32 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Neuren Pharmaceuticals Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for NEU cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Neuren Pharmaceuticals Ltd
Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd
Current Assets | 228m |
Cash & Short-Term Investments | 213.2m |
Receivables | 14.9m |
Non-Current Assets | 110k |
PP&E | 35k |
Other Non-Current Assets | 75k |
Current Liabilities | 9m |
Accounts Payable | 4.5m |
Other Current Liabilities | 4.5m |
Non-Current Liabilities | 29k |
Other Non-Current Liabilities | 29k |
Earnings Waterfall
Neuren Pharmaceuticals Ltd
Revenue
|
204.2m
AUD
|
Operating Expenses
|
-38.2m
AUD
|
Operating Income
|
166m
AUD
|
Other Expenses
|
-48.7m
AUD
|
Net Income
|
117.3m
AUD
|
Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd
AUD | |
Free Cash Flow | AUD |
Neuren had a remarkable financial year with a profit of AUD 157 million, driven by significant income streams including royalty, milestone payments from DAYBUE sales, and an expanded deal with Acadia. DAYBUE net sales for the year were USD 177 million, surpassing expectations. Guidance for 2024 indicates sales growth to USD 370-420 million, with expected royalty income of AUD 61-70 million. Milestone payments could reach USD 50 million, potentially boosting total revenue to $138 million. Beyond DAYBUE, Neuren's value is also fueled by trofinetide sales and Phase II trial results for NNZ-2591 across four indications.
What is Earnings Call?
NEU Profitability Score
Profitability Due Diligence
Neuren Pharmaceuticals Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Neuren Pharmaceuticals Ltd's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
NEU Solvency Score
Solvency Due Diligence
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NEU Price Targets Summary
Neuren Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for NEU is 27.99 AUD with a low forecast of 23.13 AUD and a high forecast of 32.49 AUD.
Dividends
Current shareholder yield for NEU is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
NEU Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The Company’s lead drug compound, Trofinetide, is in a Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. Its both programs have each received Fast Track designation by the United States Food and Drug Administration (FDA) and Orphan Drug designation in both the United States and the European Union. The firm has granted a license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America, while retaining all rights outside North America. The firm is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome and Pitt Hopkins syndrome. The company is also planning a Phase II trial in Prader-Willi syndrome.
Contact
IPO
Employees
Officers
The intrinsic value of one NEU stock under the Base Case scenario is 8.13 AUD.
Compared to the current market price of 12.32 AUD, Neuren Pharmaceuticals Ltd is Overvalued by 34%.